Explore › Intervention › OROS-MPH combined with CBT
Intervention

OROS-MPH combined with CBT

Also known as: OROS-MPH (18-72 mg/day, titrated over 2 weeks, 16-week treatment) combined with weekly CBT for substance use CBT OROS-MPH
3 findings 1 paper 4 related entities View in graph →

Related entities

conditions
Psychoactive substance use disorder1
outcomes
SUD responder status1
populations
Adolescents1
studys
PMC34996781

Findings (27)

None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →
None
improvement

Adolescents with comorbid conduct disorder who received OROS-MPH had 3.866 times the predicted odds of achieving a 50% reduction in substance use compared to those with comorbid conduct disorder who r

Effect: improvement; OR=3.866; CI: 95% CI=1.29-11.58

Size: OR=3.866 CI: 95% CI=1.29-11.58
PMC3499678
Finding details → · Paper → · Graph →

Papers (1)